PIONEER 11
Phase IIIa double-blind trial of oral semaglutide monotherapy vs placebo in a predominantly Chinese type 2 diabetes population, with HbA1c and body-weight findings. PICO summary and expert commentary.
Diabetes & Glycaemic Control
Diabetes and glycaemic-control evidence summaries covering HbA1c, glucose monitoring, medication comparisons, hypoglycaemia, patient-reported outcomes, and clinical interpretation.
PIONEER 12
PIONEER 12 was a 26-week, double-blind, manufacturer-sponsored Phase IIIa trial showing oral semaglutide lowered HbA1c and body weight more than sitagliptin in a predominantly Chinese population with type 2 diabetes. PICO summary and expert commentary.
Tirzepatide in Early-Onset Type 2 Diabetes: SURPASS Post Hoc Analysis
A post hoc analysis of the SURPASS program found tirzepatide produced similar HbA1c, weight, and cardiometabolic improvements whether type 2 diabetes was diagnosed before or after age 40. PICO summary and expert commentary.
Integrated Digital Data Platform Plus Dietary Management in Type 2 Diabetes: A 12-Week RCT
A single-center randomized controlled trial testing a cloud-hospital data platform plus dietary management against standard care in 180 adults with type 2 diabetes, reporting a modest 12-week HbA1c advantage. PICO summary and expert commentary.
Semaglutide Efficacy Across Baseline Subgroups: A Post Hoc Analysis of SUSTAIN China
A post hoc analysis of the SUSTAIN China trial found that the glycaemic efficacy of once-weekly semaglutide versus sitagliptin was consistent across most baseline subgroups. PICO summary and expert commentary.
Tirzepatide vs Semaglutide: Mechanistic Glucose Control on a Meal Test
A model-based analysis of a 28-week randomized meal-test substudy comparing tirzepatide 15 mg with semaglutide 1 mg in metformin-treated type 2 diabetes. PICO summary and expert commentary.
Intensive Blood Pressure Control (<120 mmHg) Reduces CV Events in Type 2 Diabetes: Chinese BPROAD Trial
In patients with type 2 diabetes, intensive blood-pressure control (targeting systolic BP
Efficacy and Safety of Oral Semaglutide as an Add-On to Metformin Therapy in Type 2 Diabetes: Insights from the PIONEER 3 Trial
In adults with type 2 diabetes inadequately controlled with metformin (alone or with sulfonylurea), oral semaglutide (7 mg and 14 mg) significantly reduced HbA1c and body weight compared to sitagliptin over 26 weeks, while the 3 mg dose showed no significant benefit.